Mankind Pharma Secures Relief as GST Appellate Authority Drops Rs 46.32 Lakh Penalty

Written By :  Parthika Patel
Published On 2026-02-17 18:15 GMT   |   Update On 2026-02-17 18:15 GMT
Advertisement

Mumbai: Mankind Pharma Limited has informed the stock exchanges that the Joint Commissioner of State Tax, State GST (Appeals), Nagpur, Maharashtra, has dropped a penalty demand of Rs 46,32,582 imposed earlier under the Central Goods and Services Tax (CGST) Act, 2017.

In an intimation, submitted to BSE Limited and the National Stock Exchange of India Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company stated that it has received an Order-in-Appeal dated February 16, 2026 in connection with its appeal against an earlier order passed by the Deputy Commissioner of State Tax, Nagpur, Maharashtra.

Advertisement

The appellate authority, namely the Joint Commissioner of State Tax, State GST (Appeals), Nagpur, Maharashtra, issued Order-in-Appeal No. 02/286 dated February 16, 2026. The order was passed against the Order-in-Original dated February 28, 2025, which had been issued under Section 73 of the Central Goods and Services Tax Act, 2017 for the financial year 2020-21. The earlier order had imposed a penalty demand of ₹46,32,582 on the company.

As per the latest order, the appellate authority has dropped the entire penalty demand of ₹46,32,582 that had been levied in the Order-in-Original.

The company clarified that the Order-in-Appeal dated February 16, 2026 was received in relation to the appeal filed by Mankind Pharma against the February 28, 2025 order.

In its detailed disclosure, the company stated that there are no violations or contraventions committed or alleged to have been committed in connection with the matter. It also clarified that there is no financial, operational, or other impact on the listed entity arising from the order, quantifiable in monetary terms.

Also Read: Mankind Pharma Secures Interim Injunction Against Biodiscovery Over Fendikind, Zenkind, Kind Trademarks

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News